摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-1-methyl-5-((2-(4-phenylpiperazin-1-yl)pyrimidin-4-yl)methylene)imidazolidine-2,4-dione | 1332366-66-1

中文名称
——
中文别名
——
英文名称
(Z)-1-methyl-5-((2-(4-phenylpiperazin-1-yl)pyrimidin-4-yl)methylene)imidazolidine-2,4-dione
英文别名
(5Z)-1-methyl-5-[[2-(4-phenylpiperazin-1-yl)pyrimidin-4-yl]methylidene]imidazolidine-2,4-dione
(Z)-1-methyl-5-((2-(4-phenylpiperazin-1-yl)pyrimidin-4-yl)methylene)imidazolidine-2,4-dione化学式
CAS
1332366-66-1
化学式
C19H20N6O2
mdl
——
分子量
364.407
InChiKey
BMHOIMSADPQREP-SSZFMOIBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    27
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    81.7
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • Imidazole-2,4-Dione Inhibitors of Casein Kinase 1
    申请人:Baldino Carmen M.
    公开号:US20120316155A1
    公开(公告)日:2012-12-13
    Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), the TGFβ pathway and/or the Wnt pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), the TGFβ pathway and/or the Wnt pathway.
    本发明涉及一些化合物,其中包括这些化合物的药物组合物,以及这些化合物和组合物作为酪氨酸激酶1(例如CK1γ)、TGFβ途径和/或Wnt途径的调节剂的用途。本发明还涉及用于治疗或预防一系列治疗适应症的用途,这些治疗适应症至少部分归因于酪氨酸激酶1(例如CK1γ)、TGFβ途径和/或Wnt途径的异常生理活动。
  • US9073903B2
    申请人:——
    公开号:US9073903B2
    公开(公告)日:2015-07-07
  • [EN] IMIDAZOLE-2, 4-DIONE INHIBITORS OF CASEIN KINASE 1<br/>[FR] INHIBITEURS IMIDAZOLE-2, 4-DIONE DE LA CASÉINE KINASE 1
    申请人:JASCO PHARMACEUTICALS LLC
    公开号:WO2011103289A2
    公开(公告)日:2011-08-25
    Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), the TGFβ pathway and/or the Wnt pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), the TGFβ pathway and/or the Wnt pathway.
查看更多